Can Hormone Replacement Therapy Help Plantar Fasciitis?

No clinical trial has directly tested hormone replacement therapy as a treatment for plantar fasciitis, so there is no proven answer yet. What does exist is a growing body of biological evidence showing that fascial tissue contains hormone receptors, that estrogen influences collagen turnover in connective tissue, and that some women on HRT anecdotally report less heel pain. The question sits at an intersection that medicine has only recently begun to take seriously, and the gap between biological plausibility and clinical proof remains wide.

Why Plantar Fasciitis Peaks Around Menopause

Plantar fasciitis has long been described as a mechanical problem. The traditional explanation centers on excessive tensile strain in the plantar fascia, often linked to flat feet or biomechanics that lower the arch, producing microscopic tears and chronic inflammation at the heel.¹ That framing makes sense for runners and people on their feet all day. It explains less well why plantar heel pain so frequently appears in women during their 40s and 50s, sometimes without any change in activity level or footwear.

The overlap with perimenopause and menopause is hard to ignore once you look at the demographics. Hormonal shifts during this period affect nearly every tissue in the body, from bone density to skin elasticity, and connective tissues like fascia and tendons are no exception. Yet the connection between hormones and heel pain has been strikingly under-researched. A focus group study of women with plantar heel pain found that 76% of participants did not initially perceive any association between their menopause and their heel pain, and none reported that a healthcare provider had mentioned the possibility during consultations.² The question of whether HRT could help is, in a sense, a downstream question from one that most clinicians have not yet asked their patients.

Fascia Has Hormone Receptors

The biological case for a hormone connection starts with a basic anatomical finding: fascial tissue expresses sex hormone receptors. Research on samples of human fascia collected during orthopedic surgery has confirmed that fibroblasts within the fascia carry both estrogen receptor-alpha and relaxin receptor 1. These receptors were present across multiple fascial districts and in isolated fascial fibroblast cultures, with expression notably lower in postmenopausal women compared to premenopausal women.³ Separate work has confirmed these findings, showing relaxin receptor expression was particularly concentrated around blood vessels and nerves within the fascia.⁴

What this means in practical terms is that fascia is not inert structural scaffolding. Its cells are actively listening to hormonal signals. When estrogen levels drop during menopause, the tissue loses some of that signaling input. The fibroblasts that maintain and remodel fascial tissue are working with a diminished hormonal environment, and that has real consequences for how the tissue behaves.

Estrogen, Collagen, and Tissue Stiffness

The plantar fascia is mostly collagen, so what estrogen does to collagen production matters. Lab studies on fascial cells treated with estradiol have shown that hormone levels directly modulate production of key structural proteins. Collagen-I production, for instance, dropped from about 6% positivity during the follicular phase to roughly 2% during the periovulatory phase, demonstrating that fascial cells adjust their extracellular matrix output in response to hormonal fluctuations.⁵ This was the first direct demonstration that fascia can remodel itself based on circulating sex hormones.

Research on tendons, which share a similar collagen-rich architecture with the plantar fascia, adds further detail. A study comparing postmenopausal women using estrogen replacement to non-users found that estrogen was associated with higher tendon collagen synthesis rates and a higher relative number of smaller collagen fibrils. The tendons of estrogen users also had a lower Young’s modulus, meaning they were more compliant and less stiff.⁶ The researchers described estradiol as playing a pivotal role in maintaining homeostasis of female connective tissue.

A related study using transdermal estrogen patches found that combining estrogen with exercise enhanced collagen synthesis in skeletal muscle tissue after acute loading, though the effect on the tendon tissue itself was less clear.⁷ The picture these studies paint is nuanced: estrogen appears to stimulate collagen turnover and keep connective tissue supple at rest, but the relationship between hormones, exercise, and tissue repair is not a simple “more estrogen equals better tissue.”

How the Plantar Fascia Changes with Age

Even setting hormones aside, the plantar fascia becomes stiffer with age. Sonoelastography, an imaging technique that maps tissue stiffness, has shown that older healthy adults have significantly stiffer plantar fasciae compared to younger adults. In a study using color-coded stiffness mapping, the intensity of blue (representing harder tissue) was significantly greater in older healthy subjects than in younger ones.⁸ Interestingly, people with active plantar fasciitis had a different stiffness profile than even the older healthy subjects, suggesting that the disease process involves distinct tissue changes beyond simple age-related wear.

This age-related stiffening of the fascia converges with the hormonal decline of menopause. A fascia that is already becoming less compliant with age loses additional support for collagen turnover as estrogen drops. The tissue becomes less able to repair micro-damage from normal daily use, and the mechanical threshold for developing pain goes down. You do not need to be running marathons for this to matter. Walking, standing at work, or even shifting weight differently because of joint pain elsewhere can be enough to overload tissue that has lost its resilience.

What Women on HRT Actually Report

Without randomized controlled trials, the closest we get to real-world evidence comes from patient reports. In focus groups with women who had experienced plantar heel pain during or after menopause, some participants noted that their foot pain seemed to improve after starting HRT. One participant had suspected a hormonal link and sought medical advice about it. Others only made the connection retrospectively, after discussing symptoms with friends going through similar experiences.²

These are anecdotes, not data from controlled experiments. Women who start HRT typically do so for hot flashes, sleep disruption, or bone health, and any improvement in heel pain happens alongside many other changes. Placebo effects, lifestyle shifts, and the natural tendency for plantar fasciitis to improve over time all confound the picture. Still, these reports are consistent with what the biology would predict. If estrogen helps maintain collagen turnover and tissue compliance, restoring estrogen levels through HRT could plausibly reduce the fascial degeneration that contributes to heel pain.

Why Your Doctor Probably Has Not Mentioned This

The disconnect between the emerging biological evidence and clinical practice is substantial. The focus group data makes this point starkly: not a single participant recalled a healthcare provider mentioning menopause as a possible factor in their heel pain.² This is not because clinicians are negligent. It reflects the state of the evidence: clinical guidelines for plantar fasciitis focus on stretching, orthotic support, weight management, and sometimes corticosteroid injections. Hormonal status does not appear in any major clinical practice guideline for heel pain.

The research connecting hormones to fascial tissue is still at the bench science and qualitative research stage. The receptor studies confirm a mechanism exists. The collagen synthesis studies show that estrogen influences tissue behavior. But no one has run the study that would actually change clinical practice: a randomized trial giving HRT to postmenopausal women with plantar fasciitis and measuring whether their heel pain improves more than it would with standard treatment alone. Until that trial exists, recommending HRT specifically for heel pain is not something most physicians will do.

That said, if you are already considering HRT for other menopausal symptoms, the potential effect on connective tissue health is worth knowing about. It may be a secondary benefit rather than a primary reason to start treatment, but it could factor into a broader conversation with your doctor about the risks and benefits of hormone therapy.

Other Factors That Stack Up After Menopause

Hormonal changes are not the only thing that makes plantar fasciitis more likely in midlife women. Body composition shifts play a role too. Weight gain during and after menopause increases the mechanical load on the plantar fascia with every step. Research on postmenopausal women has shown that those with obesity, particularly sarcopenic obesity where muscle mass is low but fat mass is high, experience significantly higher plantar pressures during walking. The increased loading can cause discomfort and pain and may limit basic daily activities like walking itself, creating a cycle of reduced activity and further deconditioning.⁹

Loss of the heel’s natural fat pad also accelerates with age and may be influenced by hormonal status, though the evidence here is thinner. The fat pad absorbs shock, and as it thins, more force is transmitted to the fascia. Combine a thinner fat pad, stiffer fascia, reduced collagen turnover, higher body weight, and lower muscle mass, and you have a perfect storm for heel pain that no single intervention fully addresses.

This is part of why the HRT question is both appealing and insufficient on its own. Even if estrogen replacement helps maintain fascial tissue quality, it would not reverse the effects of increased mechanical load, weakened foot muscles, or a degenerating fat pad. Any realistic approach to plantar fasciitis in menopausal women would need to address multiple factors simultaneously, with hormonal considerations as one layer rather than a standalone fix.

What You Can Do in the Meantime

If you are dealing with heel pain during or after menopause, the standard first-line approaches still matter: calf and plantar fascia stretching, supportive footwear, gradual strengthening of the intrinsic foot muscles, and managing your weight if that is relevant. These interventions have a solid evidence base regardless of hormonal status, and most cases of plantar fasciitis improve within six to twelve months with conservative management.

Where the hormonal angle becomes relevant is in framing your expectations and your conversations with healthcare providers. If your plantar fasciitis started around the time of other menopausal symptoms and standard treatments are not helping as much as expected, it is reasonable to bring up the hormonal dimension. Not every clinician will be familiar with the receptor research or the collagen synthesis data, but the body of evidence is growing, and more are becoming aware of what researchers sometimes call the musculoskeletal syndrome of menopause, a cluster of joint pain, tendon problems, and soft tissue complaints that coincide with hormonal decline.

If you are already on HRT and have noticed improvements in heel pain, that observation aligns with what the biology would predict, even though it cannot be separated from other factors without controlled data. If you are not on HRT and are considering it, plantar fasciitis alone would not typically meet the threshold for starting hormone therapy, given its risks and the availability of effective local treatments. But it may be one more item on a list of menopausal symptoms that collectively make the case for HRT stronger in your individual situation.

The Stiffness Paradox in Connective Tissue

One wrinkle in the estrogen story is worth understanding, because it complicates the simple narrative that “more estrogen equals healthier fascia.” The tendon research found that while estrogen users had more active collagen synthesis, their tendons were actually less stiff, with a lower Young’s modulus.⁶ In some contexts, less stiff connective tissue is a good thing: it means the tissue is more compliant and better able to absorb daily strain without micro-tearing. But there are also situations where reduced stiffness could mean reduced structural support, potentially increasing the risk of certain injuries.

This is a tension that runs through the entire literature on estrogen and connective tissue. Estrogen appears to keep tissues metabolically active and turning over collagen, which is good for repair. At the same time, very high estrogen levels, as seen in pregnancy, are associated with ligament laxity and sometimes increased injury risk. The sweet spot likely depends on the tissue, the mechanical demands placed on it, and the individual’s other risk factors. For the plantar fascia specifically, where age-related stiffening and degenerative micro-tearing seem to be the primary problem, a shift toward more compliant and metabolically active tissue probably helps. But the picture is not as simple as supplementing a missing ingredient and watching the problem disappear.

Why This Research Gap Persists

Given that plantar fasciitis is one of the most common musculoskeletal complaints in primary care, and that menopause affects half the population, you might wonder why no one has run the obvious trial. Part of the answer is that foot pain research and menopause research have historically lived in separate silos. Podiatrists and orthopedic surgeons focus on biomechanics and local treatments. Gynecologists and endocrinologists manage hormonal therapy. The patient with heel pain that started at 48 falls between these specialties, and neither side has traditionally considered the other’s domain.

Funding structures reinforce the divide. HRT trials tend to focus on high-stakes endpoints like cardiovascular disease, breast cancer risk, and bone fractures. Heel pain, while genuinely debilitating for the people living with it, does not compete well for research dollars against those outcomes. The result is that the receptor studies and collagen research exist as promising fragments, pointing toward a connection that no large-scale clinical study has been designed to confirm or refute.

The qualitative research, such as the focus group studies, represents a newer effort to bridge this gap by starting with patients’ experiences and working backward toward hypotheses worth testing. Researchers have been explicit that the high proportion of women who did not connect their heel pain to menopause suggests a widespread blind spot that deserves investigation.² Whether that investigation eventually leads to HRT being recommended for heel pain, or simply to better counseling about what to expect during menopause, remains to be seen. For now, the honest answer is that the biology is compelling but the clinical proof is not yet there.